Richard Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

Oncolytic Biosimilars: An Opportunity to Reduce Oncology Treatment Costs

Clinical Pathways GPS

04/21/2020

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug...

...

04/21/2020

Journal of Clinical Pathways

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Richard Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products